STORMAGIC
11.6.2024 13:01:30 CEST | Business Wire | Press release
StorMagic®, solving the world’s edge data problems, today announced SvHCI, which combines a hypervisor and virtual networking with the provider’s proven virtual storage technology used by thousands of customers around the world. This full-stack HCI (hyperconverged infrastructure) solution is purpose-built for edge and small to medium-sized business (SMB) environments and includes StorMagic’s in-house 24x7x365 customer support.
According to the 2024 Gartner® Market Guide for Full-Stack Hyperconverged Infrastructure Software, “the 30% of the non-market leading full-stack HCI installed base that exists in 2024 will increase to 60% by 2029.”* StorMagic believes that this is validating the significant and growing appetite for this type of storage and compute architecture in the market in the wake of the significant market churn witnessed this year.
StorMagic’s SvSAN® is depended on for 100% uptime by customers who currently use VMware or Microsoft hypervisors and is the foundation of the new full-stack solution. SvHCI is a software solution that installs directly on new or existing servers and includes a KVM-based hypervisor, advanced virtual networking and SvSAN as the storage software layer. Just like SvSAN, StorMagic SvHCI simplifies operations and delivers high availability for edge and SMBs environments with only two servers, while lowering software costs by up to 62% over VMware.**
“StorMagic SvHCI delivers exactly what our customers and partners are telling us they need to run applications reliably at their edge and SMB sites,” said Dan Beer, chief executive officer, StorMagic. “This solution is founded on the same tried and true SvSAN code we have been delivering to customers for more than a decade with over 50,000 installations around the world. With SvHCI, we’re helping end users transition from costly, overengineered, overprovisioned software running on VMware to our purpose-built and dependable solution, saving them up to 62% on software costs alone.”
Pricing and Availability
Generally available later this summer, SvHCI is priced starting at $2,049 for a one-year subscription for a single server and up to 2 TB of storage. StorMagic has also launched today an SvHCI Global Beta Program through which customers and partners can get early access to the software and test on their own servers. To learn more about SvHCI and apply for the Global Beta Program, click here.
* Source: Gartner, Market Guide for Full-Stack Hyperconverged Infrastructure Software, By Jeffrey Hewitt, Philip Dawson, Julia Palmer, Tony Harvey, 8 April 2024.
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.
**Range of savings is 21% to 62%. Comparisons include SvHCI 1, 3 and 5 year subscription lengths plus maximum storage capacities of 2TB, 6TB, 12TB, 24TB and 48TB. VMware comparisons are for the same subscription length and storage capacity of VMware vSphere Foundation with VMware vSAN and VMware Cloud Foundation with VMware vSAN.
About StorMagic
StorMagic is solving the world’s edge data problems. We help organizations of all types and sizes use, protect and manage their applications and data at and near the edge. Our solutions are easy to implement and maintain, and eliminate downtime to provide value anytime, anywhere. StorMagic’s solutions are simple, reliable and cost-effective, without sacrificing enterprise-class features, for SMBs to Fortune 500 companies with one to thousands of sites.
Join the Conversation
Follow StorMagic on Facebook, Instagram, LinkedIn, and Twitter, and subscribe to our corporate blog and YouTube channel.
StorMagic, SvSAN, SvKMS and SvHCI are trademarks of StorMagic.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240611750413/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom